CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

First International Summit on Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

May

Today In Oncology

Propofol Exposure and Neurocognitive Outcomes in Children With High-Risk ALL

Trends in Hematopoietic Cell Transplantation Survival Rates Across Racial and Ethnic Groups

USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer

Combination of Preketone Supplements and Immunotherapy May Be Effective in Patients With Prostate Cancer

Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos